Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
NEW YORK, April 28, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased INSYS Therapeutics, Inc. (“INSYS”) (NASDAQ:INSY) securities between February 23, 2016 and March 15, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sa/insys-therapeutics-inc-3. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) INSYS had overstated its 2015 net revenue; (2) INSYS had misstated its sales allowances for 2016; (3) accordingly, the Company lacked effective internal controls over financial reporting; and (4) as a result, INSYS public statements were materially false and misleading at all relevant times.
If you suffered a loss in INSYS you have until May 16, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sa/insys-therapeutics-inc-3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
